Table 2 TEAEs that occurred in > 5% of patients overall during the OLE up to and including Week 128 (SAF-OLE population)
Preferred term, n (%) | Patients who started rhPTX-2 (n = 37) | Patients who continued rhPTX-2 (n = 74) | Total (n = 111) |
|---|---|---|---|
Idiopathic pulmonary fibrosis | 11 (29.7) | 22 (29.7) | 33 (29.7) |
Dyspnea | 6 (16.2) | 26 (35.1) | 32 (28.8) |
Cough | 14 (37.8) | 16 (21.6) | 30 (27.0) |
Upper respiratory tract infection | 8 (21.6) | 18 (24.3) | 26 (23.4) |
Fatigue | 5 (13.5) | 14 (18.9) | 19 (17.1) |
Nasopharyngitis | 5 (13.5) | 13 (17.6) | 18 (16.2) |
Diarrhea | 2 (5.4) | 15 (20.3) | 17 (15.3) |
Bronchitis | 8 (21.6) | 8 (10.8) | 16 (14.4) |
Hypoxia | 5 (13.5) | 11 (14.9) | 16 (14.4) |
Arthralgia | 4 (10.8) | 8 (10.8) | 12 (10.8) |
Dizziness | 2 (5.4) | 10 (13.5) | 12 (10.8) |
Pneumonia | 3 (8.1) | 9 (12.2) | 12 (10.8) |
Back pain | 3 (8.1) | 8 (10.8) | 11 (9.9) |
Respiratory tract infection | 2 (5.4) | 9 (12.2) | 11 (9.9) |
Productive cough | 1 (2.7) | 9 (12.2) | 10 (9.0) |
Pulmonary hypertension | 4 (10.8) | 6 (8.1) | 10 (9.0) |
Dyspnea exertional | 1 (2.7) | 8 (10.8) | 9 (8.1) |
Hypertension | 2 (5.4) | 6 (8.1) | 8 (7.2) |
Rash | 1 (2.7) | 7 (9.5) | 8 (7.2) |
Blood pressure fluctuation | 3 (8.1) | 4 (5.4) | 7 (6.3) |
Gastroesophageal reflux disease | 2 (5.4) | 5 (6.8) | 7 (6.3) |
Nausea | 1 (2.7) | 6 (8.1) | 7 (6.3) |
Peripheral edema | 4 (10.8) | 3 (4.1) | 7 (6.3) |
Headache | 1 (2.7) | 5 (6.8) | 6 (5.4) |
Influenza | 2 (5.4) | 4 (5.4) | 6 (5.4) |
Pain in extremity | 2 (5.4) | 4 (5.4) | 6 (5.4) |
Pyrexia | 3 (8.1) | 3 (4.1) | 6 (5.4) |
Sinusitis | 3 (8.1) | 3 (4.1) | 6 (5.4) |